STOCK TITAN

Anson Group Files 13G/A for RNAZ — 27,125 Shares (0.1%) Disclosed

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

TransCode Therapeutics, Inc. Schedule 13G/A filed by Anson-related parties reports collective beneficial ownership of 27,125 shares of TransCode common stock, representing 0.1% of the outstanding class when including shares underlying warrants. The reporting group includes Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and principals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the 27,125 shares and no sole voting or dispositive power reported. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control of the issuer.

Positive

  • Clear disclosure of beneficial ownership totaling 27,125 shares (0.1%), including shares underlying warrants
  • Reporting includes identification of each reporting person, citizenship/place of organization and addresses

Negative

  • None.

Insights

TL;DR The disclosed stake is immaterial to control and unlikely to affect TransCode's valuation or governance.

The filing shows a combined beneficial holding of 27,125 shares (0.1%), including shares issuable upon exercise of warrants. For investors, this size is well below thresholds that typically trigger active engagement or reporting changes; the group confirms ordinary-course holding and disclaims an intent to influence control. No changes to sole voting/dispositive power were reported, and the ownership percentage calculation is clearly specified.

TL;DR Ownership is disclosed transparently and does not indicate a governance shift.

The reporting persons are identified with addresses and citizenships, and signatures certify the ordinary-course nature of the holdings. Shared voting and dispositive power is indicated, but the aggregate stake is under 5% and expressly under 1%, so there is no material influence on board control or corporate actions based on this filing alone.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Anson Funds Management LP
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Management GP LLC
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Tony Moore
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Advisors Inc.
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025
Amin Nathoo
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Moez Kassam
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025

FAQ

What stake does Anson report in TransCode Therapeutics (RNAZ)?

The reporting group discloses beneficial ownership of 27,125 shares, representing 0.1% of the outstanding common stock including warrants.

Does the filing indicate sole voting or dispositive power for the reporters?

No. The filing reports 0 sole voting power and 0 sole dispositive power, with 27,125 shares under shared voting and dispositive power.

Were the shares acquired to influence control of TransCode (RNAZ)?

The signee certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Does the 27,125 share figure include warrants?

Yes. The 0.1% figure is calculated by dividing 27,125 by 23,368,461, which includes shares underlying outstanding warrants held by the reporting group.

Who are the reporting parties named in the Schedule 13G/A?

The filers are Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and individuals Tony Moore, Amin Nathoo and Moez Kassam.
Transcode Therapeutics Inc

NASDAQ:RNAZ

RNAZ Rankings

RNAZ Latest News

RNAZ Latest SEC Filings

RNAZ Stock Data

5.91M
832.42k
0.15%
4.43%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON